Key facts, as of
As of November 2, 2026, Amgen Inc. (AMGN) trades at $467.02, up 56.5% over the past year. Its 52-week range runs from $292.12 to $475.65; the price is 1.8% below that high. It is 1.8% below its all-time high of $475.65, reached in October 2026. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +344.8%, against +316.3% for the S&P 500 (SPY). It sits 24.4% above its 200-day average of $375.47, and its 50-day average is above the 200-day too: an uptrend on both averages. Its 30-day volatility is 23.5% annualized, which we rate medium risk. It has a trailing P/E of 29.0 and a dividend yield of 2.16%. Amgen Inc. (AMGN) has confirmed its next earnings report for November 3, 2026, after the market closes (date from Yahoo Finance, listed on our November 2026 earnings calendar).
Cite: Portfolio Terminal, "Amgen Inc. (AMGN) stock analysis", 2026-11-02. https://portfolio-terminal.com/analyse/amgn
Where it trades today
trading 95% of the way up its 52-week range
How the price has moved
How far it is from its record
Amgen Inc. (AMGN) is 1.8% below its all-time high of $475.65, reached in October 2026. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +344.8%, against +316.3% for the S&P 500 (SPY).
The read, from its own figures
What its numbers say
- AMGN closes above its 50-day average ($420.52), and the 50-day sits above the 200-day ($375.47): on both averages the chart reads as an uptrend.
- At $467.02, AMGN is 1.8% below its 1-year high of $475.65, set on October 30, 2026, and 62.2% above its 1-year low of $288.00 (October 31, 2025).
- Over the past month AMGN rose 15.9%, from $403.04 to $467.02.
- AMGN trades at 29.0x its last twelve months of earnings and 19.1x the next twelve months' estimate, so analysts expect earnings 52.2% higher.
- Its P/E is 36.5% below the 45.7x median of the 3 other drug manufacturers—general companies we track (LLY, JNJ, ABBV).
- AMGN's 30-day volatility, 23.5% a year, works out to a typical daily move of about 1.5%.
- Yahoo Finance puts its beta at 0.42: over five years of monthly returns, AMGN moved about 0.42% for each 1% move of the S&P 500.
What would change the read
- A close under the 50-day average, $420.52 (−10.0% from the last close), would turn the read to a pullback; under the 200-day, $375.47 (−19.6%), the longer rise is in question.
- A close above $475.65 (+1.8%) would be a new 1-year high; below $288.00 (−38.3%), a new 1-year low.
How it is computed
- Prices are Yahoo Finance's daily candles for AMGN, the same ones the chart below draws; the P/E, forward P/E and beta are Yahoo Finance quote fields.
- The averages are simple means of the last 50 and 200 closes; the 1-year high and low are the highest high and lowest low of the last 252 sessions; the 30-day volatility is the standard deviation of the past month's daily returns, annualized with the square root of 252.
- Peers are the other companies Yahoo Finance files under drug manufacturers—general among the assets we track, not a full industry screen; the median counts those with a positive P/E.
- Every sentence here is written by code from those figures, refreshed daily; nobody edits it for AMGN by hand. It describes what the price and the multiples have done, not what they will do, and it is not advice.
Sources
- Yahoo Finance quote and daily historyopen →
The candles, the averages' inputs and the quote fields used for AMGN. Last refresh: Nov 2, 2026, 7:10 PM UTC.
- How Portfolio Terminal computes its figuresopen →
The methodology page behind the analytics and their refresh cadence.
- Industry classification
Yahoo Finance's industry, as stored in our list of tracked assets: Drug Manufacturers—General.
What Amgen Inc. does
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple…
Employees
31,500
Industry
Drug Manufacturers - General
Headquarters
Thousand Oaks, United States
What analysts expect
AMGN carries a hold consensus from 29 analysts, with an average price target of $397.32 versus $467.02 today (-14.9%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
AMGN generated $38.09B in trailing revenue (9.5% year over year), with a 23.0% net margin, and $8.65B of free cash flow, against $43.31B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $36.75B | $24.71B | $9.08B | $7.71B | $14.33 | $8.10B |
| 2024 | $33.42B | $20.57B | $7.26B | $4.09B | $7.62 | $10.39B |
| 2023 | $28.19B | $19.74B | $7.90B | $6.72B | $12.56 | $7.36B |
| 2022 | $26.32B | $19.92B | $9.57B | $6.55B | $12.18 | $8.79B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
AMGN is in 25 of the 54 ETFs we track. It weighs most in DIA: 4.94% of the fund, holding #4 of 30.
How its figures compare with those peers
Companies in the same industry
AMGN beside the other companies Yahoo Finance files under drug manufacturers—general among the assets we track (LLY, JNJ, ABBV, largest first).
AMGNyou are here$467.02$252.49B
LLYEli Lilly and Company$1406.76$1.25T
JNJJohnson & Johnson$269.63$649.10B
ABBVAbbVie Inc.$288.60$509.98BWhat the chart is saying
In an uptrend, 1.8% under its 1-year high with no resistance above.
uptrend- Price is 11.1% above its 50-day average and 24.4% above its 200-day.
- RSI at 72 is overbought: strong momentum, and stretched.
- Nothing above has stopped it this year; the nearest floor is $446.43 (-4.4%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
How is AMGN valued right now?
Amgen Inc. trades at 29.0 times its last twelve months of earnings and 19.1 times the next twelve months' estimate (Yahoo Finance, November 2, 2026). On the chart: in an uptrend, 1.8% under its 1-year high with no resistance above. Price is 11.1% above its 50-day average and 24.4% above its 200-day.
What is the risk level of AMGN?
Based on 30-day volatility of 23.5%, AMGN has MEDIUM risk. Its beta of 0.42 means it has swung less than the S&P 500 over the last five years.
Does AMGN pay dividends?
Yes, Amgen Inc. has a dividend yield of 2.16%.
How far is AMGN from its all-time high?
Amgen Inc. is 1.8% below its all-time high of $475.65, reached in October 2026. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +344.8%, against +316.3% for the S&P 500 (SPY).
When does Amgen Inc. report earnings?
Amgen Inc. (AMGN) reports its next quarterly earnings on Tuesday, November 3, 2026, after the market closes. The company has confirmed the date; it comes from Yahoo Finance's earnings data and is listed on the Portfolio Terminal November 2026 earnings calendar. For that quarter, the analysts' consensus Yahoo Finance reports is earnings of $5.78 per share.
Which ETFs hold AMGN?
25 of the 54 popular ETFs we track hold Amgen Inc.. The largest weights: DIA (4.94%), SCHD (3.89%), XLV (3.65%), CNDX (1.02%) and QQQ (1.02%). Measured on each issuer's full holdings file, dated September 30 to October 18, 2026.
How much of VOO is AMGN?
0.35%, as of September 30, 2026: AMGN is holding #50 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $3.46 in Amgen Inc..
What is the analyst price target for AMGN?
The average analyst price target for Amgen Inc. (AMGN) is $397.32 based on 29 analyst estimates, about 14.9% below the current price of $467.02. The published range runs from $225.00 to $500.00.
How much revenue does AMGN generate?
Amgen Inc. reported $38.09B in trailing twelve-month revenue. Revenue growth is running at 9.5% year over year. Net margin sits at 23.0%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare AMGN with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.